 Beam Therapeutics Inc NASDAQ: BEAM has announced new preclinical data for novel lipid nanoparticle LNP formulations for in vivo liver editing. The Company says that continued optimization of LNPs has led to a substantial increase in liver editing potency, which is believed to be a clinically relevant dose for its lead LNP program, which will be finalized later this year. 